Loading...
HLUN B logo

H. Lundbeck A/SCPSE:HLUN B Stock Report

Market Cap DKK 43.6b
Share Price
DKK 45.70
My Fair Value
DKK 48.18
5.2% undervalued intrinsic discount
1Y1.4%
7D2.7%
Portfolio Value
View

H. Lundbeck A/S

CPSE:HLUN B Stock Report

Market Cap: DKK 43.6b

H. Lundbeck (HLUN B) Stock Overview

Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details

HLUN B fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance5/6
Financial Health4/6
Dividends3/6

HLUN B Community Fair Values

Create Narrative

See what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.

US$5.3
70.2% undervalued intrinsic discount
Revenue growth
N/A
Profit Margin
30%
Future PE
20x
Share price in 2030
US$0

H. Lundbeck A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for H. Lundbeck
Historical stock prices
Current Share PriceDKK 45.70
52 Week HighDKK 49.38
52 Week LowDKK 27.20
Beta0.38
1 Month Change10.28%
3 Month Change29.32%
1 Year Change1.38%
3 Year Change85.58%
5 Year Changen/a
Change since IPO40.62%

Recent News & Updates

The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Recent updates

The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

H. Lundbeck A/S (CPH:HLUN B) Surges 25% Yet Its Low P/E Is No Reason For Excitement

May 28
H. Lundbeck A/S (CPH:HLUN B) Surges 25% Yet Its Low P/E Is No Reason For Excitement

H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Supported By Other Strong Factors

May 23
H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Supported By Other Strong Factors

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Reasonably Well

May 10
These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Reasonably Well

Why Investors Shouldn't Be Surprised By H. Lundbeck A/S' (CPH:HLUN B) 29% Share Price Plunge

Apr 13
Why Investors Shouldn't Be Surprised By H. Lundbeck A/S' (CPH:HLUN B) 29% Share Price Plunge

H. Lundbeck's (CPH:HLUN B) Upcoming Dividend Will Be Larger Than Last Year's

Mar 13
H. Lundbeck's (CPH:HLUN B) Upcoming Dividend Will Be Larger Than Last Year's

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.95

Feb 23
H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.95

H. Lundbeck (CPH:HLUN B) Is Paying Out A Larger Dividend Than Last Year

Feb 09
H. Lundbeck (CPH:HLUN B) Is Paying Out A Larger Dividend Than Last Year

Is H. Lundbeck (CPH:HLUN B) A Risky Investment?

Jan 26
Is H. Lundbeck (CPH:HLUN B) A Risky Investment?

H. Lundbeck A/S' (CPH:HLUN B) Price In Tune With Earnings

Jan 04
H. Lundbeck A/S' (CPH:HLUN B) Price In Tune With Earnings
User avatar

Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth

Strong growth of strategic brands, especially Vyepti and Rexulti, is expected to drive substantial revenue increase in Asian and emerging markets.

We Think H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Understated

Nov 21
We Think H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Understated

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Quite Sensibly

Oct 24
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Quite Sensibly

Shareholder Returns

HLUN BDK PharmaceuticalsDK Market
7D2.7%8.4%5.1%
1Y1.4%-49.9%-31.8%

Return vs Industry: HLUN B exceeded the Danish Pharmaceuticals industry which returned -49.9% over the past year.

Return vs Market: HLUN B exceeded the Danish Market which returned -31.8% over the past year.

Price Volatility

Is HLUN B's price volatile compared to industry and market?
HLUN B volatility
HLUN B Average Weekly Movement4.5%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement4.3%
10% most volatile stocks in DK Market7.9%
10% least volatile stocks in DK Market2.4%

Stable Share Price: HLUN B has not had significant price volatility in the past 3 months compared to the Danish market.

Volatility Over Time: HLUN B's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19155,700Charl van Zylwww.lundbeck.com

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
HLUN B fundamental statistics
Market capDKK 43.57b
Earnings (TTM)DKK 3.49b
Revenue (TTM)DKK 23.52b
13.0x
P/E Ratio
1.9x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HLUN B income statement (TTM)
RevenueDKK 23.52b
Cost of RevenueDKK 4.34b
Gross ProfitDKK 19.18b
Other ExpensesDKK 15.70b
EarningsDKK 3.49b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Nov 12, 2025

Earnings per share (EPS)3.52
Gross Margin81.55%
Net Profit Margin14.82%
Debt/Equity Ratio54.5%

How did HLUN B perform over the long term?

See historical performance and comparison

Dividends

2.1%
Current Dividend Yield
27%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/05 09:20
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

H. Lundbeck A/S is covered by 44 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter AnkersenABG Sundal Collier
null nullABG Sundal Collier
Kamla SinghAlphaValue